Clinical Trial Update: A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial of AUR103 calcium in HER2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• AUR103 Calcium (AUR103)

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED